DOI: 10.1002/psp4.12860

CORRIGENDUM

Corrigendum to: Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition

Shinji Yamazaki | Raymond Evers | Loeckie De Zwart

CPT: Pharmacometrics Syst. Pharmacol. (2022) **11**, 55–67. https://doi.org/10.1002/psp4.12733; published online 20 October 2021.

In the published version of Yamazaki *et al.* (2022)[1] the following errors were noticed.

1. A typographical error in Discussion (page 63): The term of K_i should be IC_{50}. Therefore, the sentence should read: For instance, the in vitro IC_{50} values for digoxin varied from 20 to 800-fold for 15 Pgp inhibitors among 22 laboratories.[43,44]
2. Duplicated rows ($V_{max,CYP3A4}$ (pmol/min/pmol), $K_{m,u,CYP3A4}$ (μM) and Active Hepatic Scalar) in Table S1.

TABLE S1 Input parameters of substrates and perpetrators in PBPK models

Parameter (units)	Itraconazole	Hydroxyitraconazole
MW/LogP/pK_a (base)	705.6/4.91/3.64	721.7/4.1/4.0
R_{BP}/$f_{u,plasma}$	0.60/0.0015	0.55/0.012
$f_{u,gut}$	1	1
Q_{gut} (L/h)[a]	11.5/4.94	—
$P_{eff,man}$ (10^{-4} cm/s)[b]	2.55/0.708	—
Intrinsic solubility (mg/ml)[b]	0.007/0.005	—
Particle size (μm)	3	—
Particle density (g/ml)	1.2	—
V_{ss} (L/kg)	4.7	4.7
V_{sac} (L/kg)/k_{in} (h^{-1})/k_{out} (h^{-1})	3.0/0.2/0.1	2.5/0.005/0
$V_{max,CYP3A4}$ (pmol/min/pmol)	45	23
$K_{m,u,CYP3A4}$ (μM)	0.023	0.040
Active uptake into hepatocyte	3.5	1
$K_{i,u,CYP3A4}$ (μM)	0.001	0.0082
$Pgp_{(liver/gut)}$ $K_{i,u}$ (μM)[c]	1.0/1.0	0.8/—

Note: Input parameters are obtained from the literature.[3]

Abbreviation: –, not applicable.

[a]Predicted in Simcyp (solution/capsule).

[b]Optimized to fit the literature data (solution/capsule).[3]

[c]Median value from the DIDB database.

REFERENCE

1. Yamazaki S, Evers R, De Zwart L. Physiologically- based pharmacokinetic modeling to evaluate in vitro- to- in vivo extrapolation for intestinal P-glycoprotein inhibition. *CPT Pharmacometrics Syst Pharmacol.* 2022;11:55-67.